Home  »  Finance   »  Aytu BioPharma Inc. (NASDAQ: AYTU) Has Outstanding...

Aytu BioPharma Inc. (NASDAQ: AYTU) Has Outstanding Potential

Aytu BioPharma Inc. (NASDAQ:AYTU) shares, rose in value on Friday, 05/13/22, with the stock price up by 9.90% to the previous day’s close as strong demand from buyers drove the stock to $0.52.

Actively observing the price movement in the last trading, the stock closed the session at $0.47, falling within a range of $0.4834 and $0.5351. The value of beta (5-year monthly) was -0.37. Referring to stock’s 52-week performance, its high was $6.18, and the low was $0.45. On the whole, AYTU has fluctuated by -48.17% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.


With the market capitalization of Aytu BioPharma Inc. currently standing at about $18.71 million, investors are eagerly awaiting this quarter’s results, scheduled for Feb 09, 2022 – Feb 14, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.58, which is expected to increase to -$0.42 for fiscal year -$2.54 and then to about -$1.13 by fiscal year 2023. Data indicates that the EPS growth is expected to be 25.10% in 2023, while the next year’s EPS growth is forecast to be 55.50%.

Analysts have estimated the company’s revenue for the quarter at $27.2 million, with a low estimate of $27.2 million and a high estimate of $27.2 million. Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $106.8 million, representing an increase of 62.70% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that AYTU’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of AYTU currently trading nearly -19.84% and -43.41% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 28.61, while the 7-day volatility ratio is showing 10.62% which for the 30-day chart, stands at 12.45%. Furthermore, Aytu BioPharma Inc. (AYTU)’s beta value is -0.12, and its average true range (ATR) is 0.07.

Data on historical trading for Aytu BioPharma Inc. (NASDAQ:AYTU) indicates that the trading volumes over the past 3 months, they’ve averaged 1.01 million. According to company’s latest data on outstanding shares, there are 26.41 million shares outstanding.

Nearly 0.30% of Aytu BioPharma Inc.’s shares belong to company insiders and institutional investors own 20.20% of the company’s shares. The stock has fallen by -61.76% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AYTU stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts



Download Free eBook For


100% free. stop anytime no spam